OncoMatch/Clinical Trials/NCT06710223
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
Is NCT06710223 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including SD-101 and Cryotherapy for hepatocellular carcinoma.
Treatment: SD-101 · Cryotherapy · Tremelimumab · Durvalumab — The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Peripheral absolute neutrophil count ≥ 1000/mm^3; Platelet count ≥ 50,000/ mm^3; Hemoglobin ≥ 8.0 g/dL
Kidney function
creatinine clearance ≥ 50 ml/min
Liver function
Child-Pugh A or Child-Pugh B7 liver function; Total bilirubin ≤ 2.0 x institution's upper limit of normal; ALT or AST ≤ 5 x institution's upper limit of normal; Albumin ≥ 2 g/dL
Cardiac function
Systolic blood pressure <160 mm Hg; no NYHA class III/IV heart failure; no myocardial infarction/active ischemic heart disease within one year; no uncontrolled dysrhythmias; no poorly controlled angina
Child-Pugh A or Child-Pugh B7 liver function. Total bilirubin ≤ 2.0 x institution's upper limit of normal. ALT or AST ≤ 5 x institution's upper limit of normal. Albumin ≥ 2 g/dL. Peripheral absolute neutrophil count ≥ 1000/mm^3. Platelet count ≥ 50,000/ mm^3. Hemoglobin ≥ 8.0 g/dL. Creatinine clearance ≥ 50 ml/min. Systolic blood pressure <160 mm Hg. Cardiac impairment defined as: prior history of cardiovascular disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions; OR history of myocardial infarction/active ischemic heart disease within one year of study entry; OR uncontrolled dysrhythmias; OR poorly controlled angina.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Diego · San Diego, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06710223 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages